HUTCHISON CHINA/S (HCM) Cut to Sell at BidaskClub
BidaskClub downgraded shares of HUTCHISON CHINA/S (NASDAQ:HCM) from a hold rating to a sell rating in a research note published on Thursday morning.
Several other brokerages have also recently commented on HCM. MED assumed coverage on HUTCHISON CHINA/S in a research report on Monday, July 23rd. They set a positive rating for the company. Zacks Investment Research cut HUTCHISON CHINA/S from a hold rating to a sell rating in a research report on Tuesday, August 21st. Two investment analysts have rated the stock with a sell rating and three have given a buy rating to the stock. The stock presently has a consensus rating of Hold and an average price target of $38.00.
HUTCHISON CHINA/S stock opened at $28.25 on Thursday. HUTCHISON CHINA/S has a 12 month low of $25.10 and a 12 month high of $42.25. The company has a quick ratio of 4.55, a current ratio of 4.67 and a debt-to-equity ratio of 0.06.
HUTCHISON CHINA/S Company Profile
Hutchison China MediTech Limited, a biopharmaceutical company, engages in the research, development, manufacture, and sale of pharmaceuticals and healthcare products primarily in the People's Republic of China and Hong Kong. It operates through Innovation Platform and Commercial Platform segments.
Read More: Investing in Growth Stocks
Receive News & Ratings for HUTCHISON CHINA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHISON CHINA/S and related companies with MarketBeat.com's FREE daily email newsletter.